InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
61,222.32
(
0.70%
)
Post# of 251791
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 80158

Wednesday, 02/22/2012 8:18:11 PM

Wednesday, February 22, 2012 8:18:11 PM

Post# of 251791
MYL-Biocon FoB portfolio:

• Herceptin: phase-1
• Neulasta: preclinical
• Avastin: process development
• Humira: cell-line development
• Enbrel*: cell-line development
• One undisclosed product at an undisclosed stage

*Presumably not for US market due to AMGN’s recent patent extension.

Source: MYL’s Investor Day webcast (2/21/12).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (6) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (6) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up